Physician profile
Wei Yan
NPI 1255827234
$2,653.54
in general payments reported to CMS, 2019-2025
26 companies · $1,402 in 2025
The $1,402 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20.88 · 2023: $719 · 2024: $512 · 2025: $1,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,632.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $505.69 | 2024-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $314.11 | 2022-2025 | Skyrizi |
| Intercept Pharmaceuticals, INC. | $296.95 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $184.07 | 2024-2025 | Entyvio, Gattex, Eohilia |
| Medtronic, INC. | $152.84 | 2023 | Barrx |
| E.R. Squibb & Sons, L.L.C. | $145.25 | 2023 | Zeposia |
| Gilead Sciences, INC. | $139.33 | 2023-2025 | Epclusa |
| Genzyme Corporation | $129.67 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.48 | 2025 | Xifaxan |
| Madrigal Pharmaceuticals | $110.74 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $99.53 | 2024-2025 | Omvoh |
| Janssen Scientific Affairs, LLC | $92.07 | 2023 | Stelara |
| Boston Scientific Corporation | $59.01 | 2023 | Resolution 360 Clip, Spyglass, Extractor Pro Rx |
| Celltrion USA INC. | $43.93 | 2025 | Vegzelma |
| Ironwood Pharmaceuticals, INC | $31.47 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $25.58 | 2024 | Zeposia |
| Pfizer INC. | $24.46 | 2025 | |
| Ardelyx, INC. | $23.40 | 2025 | Ibsrela |
| Fresenius Kabi USA, LLC | $23.21 | 2025 | Adalimumab-Aacf |
| Aimmune Therapeutics, INC. | $23.01 | 2025 | Vowst |
| Veloxis Pharmaceuticals, INC. | $22.50 | 2023 | Envarsus |
| Regeneron Healthcare Solutions, INC. | $22.27 | 2024 | Dupixent |
| Inspire Medical Systems, INC. | $20.46 | 2025 | Inspire |
| Exact Sciences Corporation | $16.16 | 2023 | Cologuard Collection Kit |
| Evoke Pharma, INC. | $15.60 | 2025 | |
| Phathom Pharmaceuticals, INC. | $10.75 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Yan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.